Accession Number: | 0001209191-19-060277 |
Date: | 2019-12-10 |
Issuer: | ODONATE THERAPEUTICS, INC. (ODT) |
Original Submission Date: |
JOHNSON CRAIG A
C/O ODONATE THERAPEUTICS, INC.
4747 EXECUTIVE DRIVE, SUITE 510
SAN DIEGO, CA 92121
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 30.51 | 2019-12-10 | deemed execution date | A | 12,500 (a) | 2029-12-10 | common stock 12,500 | $30.51 | 12,500 | direct |
ID | footnote |
---|---|
f1 | the stock options vest and become exercisable as follows: (i) 50% on the date of u.s. food and drug administration ("fda") approval of tesetaxel; (ii) 25% on the first anniversary of fda approval of tesetaxel; and (iii) 25% on the second anniversary of fda approval of tesetaxel. vesting is subject to the reporting person's continued service to the issuer through each vesting date. |